I/we claim:

1. Use of a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of rosacea or papulopustular rosacea in a subject in need thereof to thereby obtain a significant reduction in inflammatory lesion count as early as two weeks after the initial administration of the medicament without co-administration of another active ingredient, wherein the medicament is to be topically administered, once daily, to a skin area affected by the inflammatory lesions of rosacea or the papulopustular rosacea.

2. The use of claim 1, wherein the treatment results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

3. The use of claim 1 or 2, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

4. The use of any one of claims 1 to 3, wherein the treatment has a median time to first relapse of 110 days or longer.

5. The use of any one of claims 1 to 4, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

6. The use of any one of claims 1 to 5, wherein the subject has 15 or more of the inflammatory lesions before the treatment.

7. The use of any one of claims 1 to 6, wherein a steady state of plasma concentration of ivermectin is reached in the subject as early as 2 weeks after the initial administration of the medicament to the subject, wherein the steady state has a C_{max} of ivermectin of 0.5– 10 ng/mL, and an $AUC_{0\text{-}24hr}$ of 10-100 ng.hr/mL in the subject.

8. The use of any one of claims 1 to 7, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from

the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

9. The use of any one of claims 1 to 8, wherein the treatment results in a mean terminal half-life of ivermectin of about 145 hours in the subject.

10. Use of a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of rosacea or papulopustular rosacea in a subject in need thereof to thereby obtain a significant reduction in inflammatory lesion count without co-administration of another active ingredient and a steady state of plasma concentration of ivermectin in the subject as early as two weeks after the initial administration of the medicament, the steady state having a mean C_{max} of ivermectin of 2.10 ± 1.04 ng/mL with a range of 0.69 - 4.02 ng/mL, and a mean AUC_{0-24hr} of 36.14 ± 15.56 ng.hr/mL with a range of 13.69-75.16 ng.hr/mL, wherein the medicament is to be topically administered, once daily, to a skin area affected by the inflammatory lesions of rosacea or the papulopustular rosacea.

11. The use of claim 10, wherein the treatment results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

12. The use of claim 10 or 11, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

13. The use of any one of claims 10 to 12, wherein the treatment has a median time to first relapse of 110 days or longer.

14. The use of any one of claims 10 to 13, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

15. The use of any one of claims 10 to 14, wherein the subject has 15 or more of the inflammatory lesions before the treatment.

16. The use of any one of claims 10 to 15, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl

alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

17. The use of any one of claims 10 to 16, wherein the pharmaceutical composition further comprises carbomer copolymer type B; cetyl alcohol; citric acid monohydrate; dimethicone 20 Cst; edetate disodium; glycerin; isopropyl palmitate; methyl paraben; oleyl alcohol; phenoxyethanol; polyoxyl 20 cetostearyl ether; propylene glycol; propyl paraben; purified water; sodium hydroxide; sorbitan monostearate and stearyl alcohol.

18. The use of any one of claims 10 to 17, wherein the treatment results in a mean terminal half-life of ivermectin of about 145 hours in the subject.

19. The use of any one of claims 10 to 18, wherein the treatment results in about 27% or more median reduction of the inflammatory lesion counts.

20. Use of a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of rosacea or papulopustular rosacea in a subject in need thereof to thereby obtain a significant reduction in inflammatory lesion count as early as two weeks after the initial administration of the medicament without co-administration of another active ingredient, wherein the medicament is to be topically administered, once daily, to a skin area affected by the inflammatory lesions of rosacea or the papulopustular rosacea.

21. Use of a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of inflammatory lesions of rosacea or papulopustular rosacea in a subject in need thereof to thereby obtain a significant reduction in inflammatory lesion count without co-administration of another active ingredient and a steady state of plasma concentration of ivermectin in the subject as early as two weeks after the initial administration of the medicament, the steady state having a mean C_{max} of ivermectin of 2.10 ± 1.04 ng/mL with a range of 0.69 - 4.02 ng/mL, and a mean $AUC_{0\text{-}24hr}$ of 36.14 ± 15.56 ng.hr/mL with a range of 13.69-75.16 ng.hr/mL, wherein the medicament is to be topically administered, once daily, to a skin area affected by the inflammatory lesions of rosacea or the papulopustular rosacea.

22. The use of claim 20 or 21, wherein the treatment results in a greater reduction in inflammatory lesion count in the subject in comparison to that achieved by topically

administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

23. The use of any one of claims 20 to 22, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.

24. The use of any one of claims 20 to 23, wherein the treatment has a median time to first relapse of 110 days or longer.

25. The use of any one of claims 20 to 24, wherein the subject has moderate to severe papulopustular rosacea before the treatment.

26. The use of any one of claims 20 to 25, wherein the subject has 15 or more of the inflammatory lesions before the treatment.

27. The use of any one of claims 20 to 26, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.

28. The use of any one of claims 20 to 27, wherein the pharmaceutical composition further comprises carbomer copolymer type B; cetyl alcohol; citric acid monohydrate; dimethicone 20 Cst; edetate disodium; glycerin; isopropyl palmitate; methyl paraben; oleyl alcohol; phenoxyethanol; polyoxyl 20 cetostearyl ether; propylene glycol; propyl paraben; purified water; sodium hydroxide; sorbitan monostearate and stearyl alcohol.